Skip to content
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Zerafil Dosing
Response Assessment
Response Assessment: Asthma
Response Assessment: Urticaria
Response Assessment: CRSwNP
Treatment Initiation
Treatment Initiation: Asthma
Treatment Initiation: Urticaria
Treatment Initiation: CRSwNP
Control Test
Control Test: Asthma (ACT)
Control Test: Urticaria (UCT)
Control Test: Sino-Nasal Outcome Test (SNOT-22)
Contact us
Response Assessment: CRSwNP
Response Assessment: Chronic Rhinosinusitis with Nasal Polyps
Which of the following criteria have been met in the assessment of this patient’s treatment response?
1. Reduced nasal polyp size (≥1)
2. Reduced need for OCS/salvage surgery
3. Improved quality of life (SNOT-22 < 40 + improvement > MCID)
4. Improved sense of smell
5. Reduced impact of comorbidities (defined by MCID for specific type 2 disease test)
none
OCS: oral corticosteroids , SNOT-22: sino-nasal outcome test-22 , MCID: minimum clinically important difference
Hidden
SUM
Overview of the Algorithms
